Effectiveness of Daptomycin Therapy in Neutropenic Patients with Haematological Malignancies

Objective & Hypothesis:Objective: The aim of this study is to evaluate the effectiveness of daptomycin (DAP) in neutropenic patients with haematological malignancies.

📊

Key Findings & Data:Methods: We evaluated data of neutropenic patients treated with DAP in adult haematology unit of our hospital between January 2011 and April 2013.

💡

Conclusion & Impact:Neutropenia was classified as severe (

🔬Design:Research Article

📍Scope:2011 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to evaluate the effectiveness of daptomycin (DAP) in neutropenic patients with haematological malignancies. Methods: We evaluated data of neutropenic patients treated with DAP in adult haematology unit of our hospital between January 2011 and April 2013. Neutropenia was classified as severe (

Özet

Amaç: Bu çalışmada hematolojik malignitesi olan nötropenik hastalarda daptomisin (DAP)'in etkinliğinin araştırılması amaçlanmıştır. Yöntemler: Haziran 2011-Nisan 2013 tarihleri arasında yetişkin hematoloji ünitesinde DAP alan nötropenik hastalar incelendi. Nötropeni, ciddi (

🔖

Cite This Article

TARKUN, P., MERİÇ, M. K., AYNIOĞLU, A. (2022). Effectiveness of Daptomycin Therapy in Neutropenic Patients with Haematological Malignancies. Klimik Dergisi, Cilt: 28 - Sayı: 2, 72–75. https://ajindex.com/articles/573620

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (3)

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guide- line for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4): e56-93. [CrossRef] Viscoli C, Costagnola E. Prophylaxis and empirical therapy of infection in cancer patients. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Living- stone Elsevier, 2010: 3793-807. [CrossRef] Safdar A, Bodey G, Armstrong D. Infections in patients with can- cer: overview. In: Safdar A, ed. Principles and Practice of Can- cer Infectious Diseases. New York: Humana Press, 2011: 3-15. [CrossRef] Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infec- tions in patients with hematological malignancies and solid ne- oplasms in hospitals in the United States. Clin Infect Dis. 2003; 36(9): 1103-10. [CrossRef] Rolston KV, McConnell SA, Brown J, Lamp KC. Daptomycin use in patients with cancer and neutropenia: data from a retrospec- tive registry. Clin Adv Hematol Oncol. 2010; 8(4): 249-56, 90. Salavert M, Calabuig E. Role of daptomycin in the treatment of infections in patients with hematological malignancies. Med Clin (Barc). 2010; 135(Suppl. 3): 36-47. [CrossRef] Galloway A, Kroger N, Keil F, et al. Results from European Cubicin Outcomes Registry and Experience: daptomycin is effective and well-tolerated in patients with neutropenia and Gram-positive infections [Abstract]. In: Abstracts of 21stEuropean Congress of Clinical Microbiology and Infectious Diseases (Milan, Italy, May 7-10, 2011).
Basel, Switzerland: European Society of Clinical Microbriology and Infectious Diseases: P2091.
Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febri- le neutropenic cancer patients. Int J Antimicrob Agents. 2007; 30(1): 51-9. [CrossRef] Ellis M. Febrile neutropenia. Ann N Y Acad Sci. 2008; 1138: 329-50. [CrossRef] Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis. 2003; 36(2): 149-58. [CrossRef] Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KV. Bacterial infections in low-risk, febrile neutropenic patients. Cancer. 2005; 104(2): 422-6. [CrossRef] Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of